Mangoceuticals vs Nexalin Technology
MGRX and NXL side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MGRX and NXL compare
Nexalin Technology is the larger company, worth 9.9 times as much as Mangoceuticals ($34.4M against $3.5M).
Nexalin Technology grew revenue faster over the last twelve months (24.2% versus −38.9% for Mangoceuticals).
Nexalin Technology keeps more of each dollar of sales as profit, with a net margin of −4139% compared with −4791% at Mangoceuticals.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MGRX | NXL |
|---|---|---|
| Size and price | ||
| Market cap | $3.5M | $34.4M |
| Share price | $0.160 | $1.56 |
| Change, 1 year | −86.5% | −95.6% |
| Beta (5Y) | −1.16 | 2.73 |
| Employees | – | 8 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 11.0× (better) | 158× |
| P/B | 0.3× (better) | 22.6× |
| Growth | ||
| Revenue growth (TTM) | −38.9% | 24.2% (better) |
| Profitability | ||
| Gross margin | 54.4% | 86.2% (better) |
| Operating margin | −3829% (better) | −4203% |
| Net margin | −4791% | −4139% (better) |
| Return on equity | −95.1% (better) | −240% |
| Return on invested capital | −60.7% (better) | −2105% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 0.18 | 1.25 (better) |
| Altman Z-score | −6.11 (better) | −41.21 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 5.6% | 0.13% |
| Held by insiders | 57.8% | 22.3% |
| Insider net buying, 12 months | −$21.2K | – |
| Short interest, % of float | 0.59% | 0.07% |
Go deeper
- MGRX stock overview
- MGRX income statement
- MGRX valuation and score
- NXL stock overview
- NXL income statement
- NXL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.